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INTRODUCTION
Castleman disease (CD) is a rare idiopathic atypical lym-
phoproliferative disorder,1 with two major histological vari-
ants, designated hyaline vascular (HV-CD) and plasma cell 
(PCD), according to histopathological findings of the affected 
lesions.2,3   The typical characteristics associated with HV-CD 
include concentric proliferation of mantle zone lymphocytes 
with hyalinized vascular proliferation in germinal centers and 
interfollicular areas.3   In contrast, PCD is characterized by 
dense mature plasma cell proliferation in expanded interfol-
licular areas.3   PCD patients often present with systemic 
manifestations, including fever with abnormal laboratory 
findings such as anemia, hypoalbuminemia, high C-reactive 
protein (CRP), and hypergammaglobulinemia.4   These char-
acteristics are believed to be caused by dysregulated overpro-
duction of interleukin (IL)-6, which is a pleiotropic cytokine 
that regulates immune responses.5
IgG4-related disease (IgG4-RD) is a recently recognized 
systemic syndrome characterized by mass-forming lesions 
and a high serum IgG4 level.6   The disease involves fibrosis 
and severe lymphoplasmacytic infiltration with abundant 
IgG4-positive cells in various organs, including lymph 
nodes.7,8   IgG4-related lymphadenopathy often lacks fibrosis 
and phlebitis, in contrast to other lesions affected in 
IgG4-RD.8,9   Five histological subtypes have been described: 
multicentric Castleman-like (type I), reactive follicular 
hyperplasia-type (type II), interfollicular expansion and 
immunoblastosis (type III), progressively transformed germi-
nal centers (PTGC)-type (type IV), and inflammatory pseu-
dotumor-like (type V).8,10
As both PCD and IgG4-RD are multi-organ disorders 
with similar histological features of a plasma cell-rich inflam-
matory infiltrate, it is sometimes difficult to histologically 
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differentiate PCD from IgG4-RD.11   Furthermore, PCD fre-
quently presents with variable lesions infiltrated by large 
numbers of IgG4-positive plasma cells, accompanied by high 
serum IgG4 levels.11,12
Moreover, hemosiderin deposition has regularly been 
observed in lymph node lesions of PCD patients.   Thus, we 
assessed the usefulness of hemosiderin deposition in differ-
entiating between PCD and IgG4-RD.
METHODS AND MATERIALS
Patient selection
Tissue specimens of lymph nodes were examined from 
22 patients with PCD and 12 patients with IgG4-RD.   All 
patients were retrieved from the surgical pathology consulta-
tion files of the Department of Pathology, Okayama 
University, Japan.   The study protocol was approved by the 
Institutional Review Board of Okayama University, 
Okayama, Japan.
PCD patients with available laboratory data were exam-
ined.   They were diagnosed based on clinical, laboratory, and 
pathological findings.   The PCD patients consisted of 15 
males and seven females aged 35 to 68 years (mean = 52.18 
years).   In addition, 14 and seven patients presented with 
multiple and localized lymph node swelling, respectively. 
From the 22 PCD patients, nine inguinal, seven cervical, 
three axillary, one intra-abdominal, one supraclavicular, and 
one mediastinum lymph node biopsy specimen were exam-
ined.   Extra nodal lesions were also detected in 14. 
Laboratory data are summarized in Table 1.
IgG4-RD patients diagnosed according to a previous 
report consisted of six males and six females aged 36 to 82 
years (mean = 60.8 years).7   Of the 12 patients, three pre-
sented with systemic lymph node swelling and nine with 
localized lymph node swelling.   Furthermore, six cervical, 
one axillary, one mediastinum, one inguinal, one submaxil-
lary, one supraclavicular, and one parotid lymph node biopsy 
specimen were examined.   Histological subtypes of these 
IgG4-related lymphadenopathy samples consisted of five 
cases of type I, two cases of type II, and five cases of type IV. 
Extra nodal lesions were also detected in four patients. 
Laboratory data are summarized in Table 1.
Histological examination
Surgically biopsied lymph node specimens were fixed in 
10% formaldehyde and embedded in paraffin.   Serial 
4-μm-thick sections were cut from paraffin-embedded tissue 
blocks, and stained with hematoxylin and eosin (HE).
Prussian blue staining
Non-stained 4-μm-thick sections were deparaffinized 
with 100% xylene, followed by replacement of xylene with 
100% alcohol, and finally washed with distilled water.   The 
specimens were treated with a solution containing a mixture 
of potassium ferrocyanide and hydrochloric acid for 30 min-
utes, and washed with distilled water.   They were then 
treated with Kernechtrot for 5 minutes and washed with dis-
tilled water.   They were dehydrated with 100% alcohol, 
cleared with 100% xylene, and finally covered with a cover-
slip and water-soluble mounting medium.   The number of 
Prussian blue-positive cells was counted in areas exhibiting 
the highest density of Prussian blue-positive cells in three 
high-power fields (3HPFs).
Statistical analysis
Data are shown as the median value ± standard deviation 
(SD).   Comparisons between two groups were performed by 
a non-parametric version of the Mann-Whitney U test. 
Spearman rank-based correlation coefficients were used to 
estimate the correlation between two continuous variables, 
and corresponding P-values were calculated.   All data were 
Variable PCD (median±SD) IgG4-RD (median±SD) P References (range)
Number 22 12 — —
Age 51.00±9.73 62.00±11.99 0.044 —
Sex 7F/15M 6F/6M — —
WBC [μL] 6570.00±2139.27† 6445±1723.69‡ 0.308 3900-9800
RBC [×104/μL] 392±69.99† 437.5±45.01‡ 0.195 M:420-554/F:384-488
Hb [g/dl] 11.1±1.79† 13.25±1.50‡ <0.001 M:13.5-17.6/F:11.3-15.2
Fe [ug/dl] 29±15.36† 78±15‡ 0.041 80-140
Plt [×10000] 38.8±13.4† 20.75±4.82‡ <0.001 12.7-35.6
Alb [g/dl] 2.8±0.83† 4.1±0.93‡ 0.088 3.9-4.9
CRP [mg/dl] 5.68±3.12† 0.08±0.99‡ <0.001 <0.30
IgG [mg/dl] 4453±1416.51† 1577.35±1973.37‡ 0.003 870-1700
IgG4 [mg/dl] 563.5±442.36† 326±783.82‡ 0.706 4.8-105
IL-6 [pg/mL] 16.1±12.09† 2.3‡ — <4.0
Table 1. Laboratory data
Hb, hemoglobin; Fe, iron; Plt, platelet; Alb, albumin; CRP, C-reactive protein; IL-6, interleukin-6; IgG4-RD, IgG4-related disease; PCD, 
plasma cell-type Castleman disease;  RBC, red blood cell; WBC, white blood cell.
† WBC, RBC, Hb, Fe, Plt, Alb, CRP, IgG, IgG4, and IL-6 were available for 21, 16, 21, 13, 21, 16, 21, 21, 17, and 16 patients, respectively.
‡ WBC, RBC, Hb, Fe, Plt, Alb, CRP, IgG, IgG4, and IL-6 were available for 12, 12, 11, 2, 12, 9, 11, 10, 9, and 1 patient, respectively.
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analyzed using SPSS software v.21.0 (SPSS Inc., Chicago, 
IL, USA).   Results with P<0.05 were regarded as significant.
RESULTS
Hemosiderin deposition
Lymph node specimens from both PCD and the five cases 
of Type I IgG4-related lymphadenopathy showed atrophic to 
hyperplastic germinal centers and expanded interfollicular 
areas with sheets of plasma cells.   Two cases of Type II 
IgG4-related lymphadenopathy exhibited hyperplastic germinal 
centers and mature plasma cell infiltration in interfollicular 
areas.   Five cases of Type IV IgG4-related lymphadenopathy 
showed follicular hyperplasia with PTGC; abundant plasma 
cells were found to infiltrate the germinal centers, and many 
eosinophils were observed in the interfollicular zone. 
Macrophages were also observed in the interfollicular areas 
of PCD and IgG4-RD.   Following HE staining, hemosiderin 
was detected in macrophages as a granular yellow-brown 
pigment in PCD, whereas little hemosiderin was detected in 
IgG4-RD (Fig. 1).   Prussian blue staining clearly revealed 
hemosiderin deposition.   Prussian blue-positive cells were 
detected in interfollicular areas of PCD specimens, whereas 
Fig. 1. Histological examination and Prussian blue staining
(a, c, e) Plasma cell-type Castleman disease (PCD) (b, d, f) IgG4-related disease (IgG4-RD) (a, b) HE staining 
(c, d, e, f) Prussian blue staining. (a, b) Hemosiderin deposition was observed in PCD, but not in IgG4-RD. (c) 
Prussian blue staining revealed hemosiderin deposition in the interfollicular area of PCD specimens. (d) 
Hemosiderin deposition was not detected or was rarely observed in typical cases of IgG4-RD. (e, f) 
Hemosiderin deposition was observed in macrophages. (f) Prussian blue-positive cells in IgG4-RD were not 
morphologically different from those in PCD.
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no or very few Prussian blue-positive cells were seen in 
IgG4-RD cases (Fig. 1).   The median number of Prussian 
blue-positive cells in PCD and IgG4-RD cases was 13 ± 36 
cel ls /3HPFs ( range:  0-113 cel ls /3HPFs)  and 4  ± 8 
cells/3HPFs (range: 1-27 cells/3HPFs) (Fig. 2) (P = 0.034). 
The median number of Prussian blue-positive cells in Type I 
IgG4-RD cases  [12 ± 10 cel ls /3HPFs (range:  1-27 
cells/3HPFs)] was higher than that in Type II [5 ± 2 
cells/3HPFs (range: 3-6 cells/3HPFs) (P = 0.439)] and Type 
IV [3 ± 5 cells/3HPFs (range: 2-15 cells/3HPFs) (P = 0.341)].
Association between hemosiderin deposition and anemia-
related markers
An exploratory correlation analysis was performed to 
examine the relationship between hemosiderin deposition and 
anemia-related markers such as serum iron levels and serum 
hemoglobin values.   Serum iron levels were examined in 13 
patients with PCD (range: 16-69 μg/dl).   No correlation was 
observed between hemosiderin deposition and serum iron 
levels (r = -0.078, P = 0.799) (Fig. 3).   The median serum 
hemoglobin value in PCD was 11.10 ± 1.79 (g/dl) (range: 
7.1-13.2 g/dl).   A non-significant positive correlation was 
observed between serum hemoglobin levels and number of 
Prussian blue-positive cells in 3HPFs (r = 0.3793, P = 0.09) 
(Fig. 3).
Relationship between hemosiderin deposition and serum 
IL-6/CRP
Serum IL-6 levels were high in all available PCD cases 
(n = 16).   The median serum IL-6 level in PCD was 16.1 ± 
12.09 (pg/mL).   A correlation was observed between serum 
IL-6 levels and the number of Prussian blue-positive cells in 
3HPFs; however, it was not significant (r = 0.3352, P = 
0.204) (Fig. 3).
The correlation between serum CRP levels and hemosid-
erin deposition in PCD was assessed in PCD cases (n = 21). 
Fig. 2. Hemosiderin deposition counts in PCD and IgG4-RD
Prussian blue-positive cells in PCD and IgG4-RD are shown in box-
plots with whiskers, representing minimum to maximum values. 
Differences between the two groups were evaluated by the Mann-
Whitney U test (*P < 0.05). More Prussian blue-positive cells were 
observed in PCD than in IgG4-RD.
Fig. 3. Relationship between hemosiderin deposition and serum Fe/Hb/IL-6/ CRP in PCD
Correlation between number of Prussian blue-positive cells in three high-power fields (3HPFs) and 
serum (a) iron, (b) hemoglobin, (c) IL-6, and (d) CRP. The positive correlation between CRP levels 
and hemosiderin in 3HPFs was significant (P < 0.05).
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In all the cases, serum CRP levels exhibited levels above the 
reference range.   The positive correlation between CRP lev-
els and hemosiderin deposition in 3HPFs was significant (r = 
0.4420, P = 0.045) (Fig. 3).
DISCUSSION
In this study, hemosiderin deposition was densely 
observed in PCD patient samples, whereas sparse or no depo-
sition was seen in IgG4-RD.   It is sometimes difficult to dis-
tinguish PCD from IgG4-RD, as they have similar histologi-
cal features including plasma cell infiltration in the 
interfollicular areas; additionally, PCD patient lymph nodes 
can also exhibit abundant infiltration of IgG4-positive 
cells.11,12   Specific characteristics have been reported as use-
ful in differentiating PCD from IgG4-RD, including the pres-
ence of IgA-positive cells in PCD, and eosinophilic infiltra-
tion observed in IgG4-RD.11,13   Furthermore, hemosiderin 
deposition appears to be useful in differentiating between the 
two diseases.   A useful approach to distinguish PCD from 
IgG4-RD may, therefore, be to evaluate a combination of fac-
tors including hemosiderin deposition, presence of IgA-
positive cells, and eosinophil infiltration.   Currently, how-
ever, the differential diagnosis between the two diseases 
requires comprehensive diagnostic procedures based on not 
only histopathological findings, but also laboratory data and 
clinical findings.3
Hemosiderin is an iron-storage complex observed as a 
granular yellow-brown degradation product on HE staining. 
The deposit is tiny and often inconspicuous, unless using 
Prussian blue staining.   Hemosiderin originates from the 
breakdown of hemoglobin or from an abnormal metabolic 
pathway of ferritin.14   When damaged or destroyed erythro-
cytes leave a ruptured blood vessel, they may release hemo-
globin into the extracellular space.   The damaged red blood 
cells or the released hemoglobin can then be phagocytosed 
by macrophages.14   As hepcidin is known to not only inhibit 
intestinal iron absorption, but also block iron release from 
macrophages,15 hemosiderin deposition can be increased 
when hepcidin is upregulated.   Moreover, as IL-6 is known 
to be a key inducer of hepatic hepcidin synthesis,16 overex-
pression of hepcidin is likely to be associated with hemosid-
erin deposition in the tissues of patients with PCD.
Overproduction of IL-6 has been suggested to drive PCD 
development.5   Although the positive relationship between 
hemosiderin deposition and serum IL-6 levels in our study 
was not significant, a positive correlation between serum 
CRP levels and hemosiderin deposition was observed.   As 
CRP expression is induced by IL-6 during inflammation, 
CRP has been considered as a relevant biomarker for indirect 
measurement of IL-6 bioactivity.17,18   Thus, we propose 
hemosiderin deposition to be associated with PCD disease 
activity.
It is well documented that PCD causes microcytic ane-
mia, mimicking iron-deficiency anemia.1   The PCD patients 
in our study also presented with anemia and low serum iron 
levels.   Although PCD patients with severe anemia were 
speculated to have high disease activity and show abundant 
hemosiderin deposition, our data showed no significant rela-
tionship between hemosiderin deposition and serum iron or 
hemoglobin levels.   This might be because anemia counter-
acts the effects of IL-6 on hepcidin production.   Plasma 
erythropoietin (EPO) has been reported to mediate hepcidin 
suppression in response to altered hematopoietic activity.19 
As anemia deteriorates, EPO concentrations increase, leading 
to the downregulation of IL-6-induced hepcidin production.20
CONCLUSION
Hemosiderin was clearly deposited in lymph node speci-
mens from patients with PCD.   This finding may be useful in 
differentiating between PCD and IgG4-RD.   Hepcidin may 
be closely related to hemosiderin deposition in PCD.   Our 
study suggested that PCD disease activity is positively corre-
lated with hemosiderin deposition.
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